Holen Sie sich die Stockscreener-App
2.47
2.92%
0.07
Handel nachbörslich:
2.42
-0.05
-2.02%
Schlusskurs vom Vortag:
$2.40
Offen:
$2.37
24-Stunden-Volumen:
1.01M
Relative Volume:
0.58
Marktkapitalisierung:
$289.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-134.24M
KGV:
-1.3955
EPS:
-1.77
Netto-Cashflow:
$-121.34M
1W Leistung:
+0.82%
1M Leistung:
+21.08%
6M Leistung:
-51.85%
1J Leistung:
-51.09%
1-Tages-Spanne:
$2.30
$2.53
1-Wochen-Bereich:
$2.30
$2.53
52-Wochen-Spanne:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650)-822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie ANNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.47 | 289.65M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025 - MarketScreener
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop - GuruFocus
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewswire
Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Park Avenue Securities LLC - Defense World
Market Highlights: Annexon Inc (ANNX) Ends on a Low Note at 2.49 - DWinneX
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
49,062 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Estimates Annexon FY2026 Earnings - Defense World
Annexon Biosciences Holds Annual Stockholders Meeting - TipRanks
Two Sigma Advisers LP Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Squarepoint Ops LLC Sells 49,438 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Millennium Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Transcript : Annexon, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
BNP Paribas Financial Markets Makes New $59,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
ProShare Advisors LLC Buys 14,475 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Jane Street Group LLC - Defense World
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference | ANNX Stock News - GuruFocus
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Nuveen Asset Management LLC Acquires 164,915 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Janus Henderson Group PLC Invests $177,000 in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Ameriprise Financial Inc. - Defense World
Deutsche Bank AG Acquires 28,448 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Northern Trust Corp - Defense World
Annexon reports promising Guillain-Barré treatment results By Investing.com - Investing.com India
Annexon (ANNX) Highlights Promising Results from Tanruprubart Ph - GuruFocus
Annexon reports promising Guillain-Barré treatment results - Investing.com Australia
Annexon Showcases Tanruprubart Data Demonstrating Improved Clini - GuruFocus
Annexon Showcases Tanruprubart Data Demonstrating Improved - GlobeNewswire
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - The Manila Times
New GBS Drug Shows 3X Better Outcomes Than Standard Care in Clinical Trial | ANNX Stock News - Stock Titan
Annexon Inc (NASDAQ: ANNX) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Annexon Inc-Aktie (ANNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
| Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):